OraSure Technologies (NASDAQ:OSUR) Upgraded at StockNews.com

OraSure Technologies (NASDAQ:OSUR) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday.

Separately, Evercore ISI cut their target price on OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating on the stock in a research report on Thursday, April 4th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, OraSure Technologies has an average rating of “Moderate Buy” and a consensus price target of $6.38.

OraSure Technologies Stock Down 2.0 %

Shares of NASDAQ:OSUR opened at $5.29 on Wednesday. The firm has a fifty day simple moving average of $6.27 and a two-hundred day simple moving average of $6.81. OraSure Technologies has a 52 week low of $4.38 and a 52 week high of $8.45. The stock has a market capitalization of $404.74 million, a P/E ratio of 7.35 and a beta of 0.15.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.22 EPS for the quarter, topping the consensus estimate of $0.13 by $0.09. OraSure Technologies had a return on equity of 14.50% and a net margin of 13.23%. The company had revenue of $75.88 million during the quarter, compared to analyst estimates of $74.13 million. During the same quarter last year, the business posted $0.21 earnings per share. The firm’s revenue was down 38.3% on a year-over-year basis. On average, analysts expect that OraSure Technologies will post -0.11 earnings per share for the current year.

Institutional Trading of OraSure Technologies

Institutional investors have recently added to or reduced their stakes in the company. AJOVista LLC bought a new stake in shares of OraSure Technologies during the fourth quarter worth $39,000. Tocqueville Asset Management L.P. purchased a new stake in OraSure Technologies in the 3rd quarter valued at about $75,000. Pathstone Family Office LLC bought a new position in OraSure Technologies in the 3rd quarter worth about $80,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of OraSure Technologies during the fourth quarter worth approximately $113,000. Finally, Baader Bank Aktiengesellschaft purchased a new stake in shares of OraSure Technologies in the fourth quarter valued at approximately $115,000. Institutional investors own 93.50% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.